The FDA’s On­co­log­ic Drugs Ad­vi­so­ry Com­mit­tee vot­ed 8-0 against a new in­di­ca­tion for Pfiz­er’s Talzen­na in com­bi­na­tion with Xtan­di for first-line treat­ment of adults with … Get free ...